SA 3443

a cyclic disulfide compound with hepatoprotective effects; posssible protective agent in treatment of liver diseases; RN given refers to (R)-isomer; RN for cpd without isomeric designation not available 8/91

Also Known As:

Networked: 7 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Matsuoka, Hidehito: 1 article (11/2005)
2.	Muranaka, Kimimasa: 1 article (11/2005)
3.	Ohashi, Koji: 1 article (11/2005)
4.	Senda, Toshihiko: 1 article (11/2005)
5.	Takahashi, Hidenori: 1 article (11/2005)
6.	Tamaki, Yasuhiro: 1 article (11/2005)
7.	Usui, Tomohiko: 1 article (11/2005)
8.	Yanagi, Yasuo: 1 article (11/2005)

Related Diseases

1.	Wounds and Injuries (Trauma) 09/01/1991 - "These findings indicate that SA3443 protects the liver against chronic liver injuries induced by CCl4 and heterogeneous serum." 01/01/1991 - "These results suggest that SA3443 provides considerable protection against immunological liver injuries, and that the efficacy of SA3443 might be partially related to an inhibition of the increase in lymphocyte-activating factor activity." 09/01/1991 - "The protective effects of SA3443, a novel cyclic disulfide, on chronic liver injuries in rats." 01/01/1991 - "Protective effect of (4R)-hexahydro-7,7-dimethyl-6-oxo-1,2,5-dithiazocine-4-carboxylic acid (SA3443), a novel cyclic disulfide, on immunologically induced liver injuries in mice." 02/01/1991 - "The effects of SA3443, a novel cyclic disulfide compound, on acute liver injuries induced by carbon tetrachloride (CCl4), D-galactosamine and DL-ethionine were studied in rats or mice. "
2.	Necrosis 09/01/1991 - "In the histopathological studies, treatment with SA3443 resulted in a decrease in the degree of hepatic necrosis, fibrosis and steatosis. "
3.	Fibrosis (Cirrhosis) 09/01/1991 - "In the histopathological studies, treatment with SA3443 resulted in a decrease in the degree of hepatic necrosis, fibrosis and steatosis. "
4.	Choroidal Neovascularization 11/07/2005 - "In vivo, the administration of SA3443 to mice with laser-induced choroidal neovascularization (CNV) suppressed the leakage from the lesions and reduced their size. " 11/07/2005 - "Suppression of laser-induced choroidal neovascularization by oral administration of SA3443 in mice."
5.	Acute Liver Failure (Fulminant Hepatic Failure) 01/01/1991 - "SA3443 reduced the lethal acute hepatic failure at doses of 100 to 300 mg/kg. Moreover, a distinct increase in lymphocyte-activating factor activity was detected in the supernatant of the culture medium of the liver macrophage/Kupffer cells isolated from the rat treated with P. "

Related Drugs and Biologics

1.	Disulfides
2.	Interleukin-1 (Interleukin 1)
3.	Carboxylic Acids
4.	Carbon Tetrachloride (Tetrachloromethane)
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
6.	Messenger RNA (mRNA)
7.	Proteins (Proteins, Gene)
8.	Immunosorbents
9.	Glutathione (Reduced Glutathione)
10.	Glucocorticoids

Related Therapies and Procedures

1.	Lasers (Laser)
2.	Oral Administration